دورية أكاديمية
أعرض في EDS

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

التفاصيل البيبلوغرافية
العنوان: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
المؤلفون: Lainez, Nuria, García-Doñas, Jesús, Esteban, Emilio, Puente, Javier, Sáez, M Isabel, Gallardo, Enrique, Pinto-Marín, Álvaro, Vázquez-Estévez, Sergio, León, Luis, García-Carbonero, Icíar, Suárez-Rodríguez, Cristina, Molins, Carmen, Climent-Durán, Miguel A, Lázaro-Quintela, Martín, González del Alba, Aranzazu, Méndez-Vidal, María José, Chirivella, Isabel, Afonso, Francisco J, López-Brea, Marta, Sala-González, Nuria, Domenech, Montserrat, Basterretxea, Laura, Santander-Lobera, Carmen, Gil-Arnáiz, Irene, Fernández, Ovidio, Caballero-Díaz, Cristina, Mellado, Begoña, Marrupe, David, García-Sánchez, José, Sánchez-Escribano, Ricardo, Fernández Parra, Eva, Villa Guzmán, José C, Martínez-Ortega, Esther, González, María Belén, Morán, Marina, Suárez-Paniagua, Beatriz, Lecumberri, María J, Castellano, Daniel
المساهمون: Lainez,N, Lecumberri,MJ Department of oncology, Complejo Hospitalario de Navarra, Servicio Oncología Médica, Navarra, Spain, García-Doñas,J Hospital Sanchinarro, Departamento Oncología, Spain, Esteban,E Hospital Universitario Central de Asturias, Departamento de Oncología, Oviedo, Spain, Puente,J Hospital Clínico de Madrid, Departamento de Oncología, Madrid, Spain, Sáez, MI Hospital Universitario Clínico Virgen de la Victoria, Departamento de Oncología, Málaga, Spain, Gallardo,E Parc Tauli Sabadell Hospital Universitario, Departamento de Oncología, Sabadell, Spain, Pinto-Marín,A Hospital Universitario La Paz, Departamento de Oncología, Madrid, Spain, Vázquez-Estévez,S Hospital Universitario Lucus Augusti, Departamento de Oncología, Lugo, Spain, León,L Hospital Santiago de Compostela, Departamento de Oncología, Santiago de Compostela, Spain, García-Carbonero,I Hospital Virgen de la Salud, Departamento de Oncología, Toledo, Spain, Suárez-Rodríguez,C Hospital Valle de Hebrón, Departamento de Oncología, Barcelona, Spain, Molins,C Hospital Universitario Dr. Peset, Departamento de Oncología, Valencia, Spain, Climent-Durán,MA Instituto Valenciano de Oncología, Departamento de Oncología, Valencia, Spain, Lázaro-Quintela,M Complexo Hospitalario Universitario de Vigo, Departamento de Oncología, Vigo, Spain, González del Alba,A Hospital Universitario Son Espases, Departamento de Oncología, Palma de Mallorca, Spain, Méndez-Vidal,MJ Hospital Universitario Reina Sofía, Departamento de Oncología, Córdoba, Spain, Chirivella,I Hospital Clínico de Valencia, Departamento Oncología, Valencia, Spain, Afonso,FJ Complejo Hospitalario Arquitecto Marcide, Departamento de Oncología, Ferrol, Spain, López-Brea,M Hospital Marqués de Valdecilla, Departamento de Oncología, Santander, Spain, Sala-González,N ICO Girona, Departamento de Oncología, Girona, Spain, Domenech,M Hospital Althaia Xarxa Asistencial Manresa, Departamento de Oncología, Barcelona, Spain, Basterretxea,L Hospital Donostia, Departamento de Oncología, San Sebastián, Spain, Santander-Lobera,C Hospital Miguel Servet, Departamento de Oncología, Zaragoza, Spain, Gil-Arnáiz,I Hospital Reina Sofía, Departamento Oncología, Tudela, Spain, Fernández,O Hospital Santa María Nai, Complejo Hospital Ourense, Departamento de Oncología, Orense, Spain, Caballero-Díaz,C Hospital Gen Universitario Valencia, Departamento de Oncología, Valencia, Spain, Mellado,B Hospital Clinic de Barcelona, Departamento de Oncología, IDIBAPS, Barcelona, Spain, Marrupe,D Hospital Universitario de Móstoles, Departamento de Oncología, Madrid, Spain, García-Sánchez,J Hospital Arnau Vilanova, Departamento de Oncología, Valencia, Spain, Sánchez-Escribano,R Hospital Universitario de Burgos, Departamento de Oncología, Burgos, Spain, Fernández Parra,E Hospital Universitario de Valme, Departamento de Oncología, Sevilla, Spain, Villa Guzmán,JC Hospital de Ciudad Real, Departamento de Oncología, Ciudad Real, Spain, Martínez-Ortega,E Hospital Ciudad de Jaén, Departamento de Oncología, Jaén, Spain, González,MB Hospital Son Llatzer, Departamento de Oncología, Palma de Mallorca, Spain, Morán,M Pfizer Madrid, Spain, Suárez-Paniagua,B Trial Form Support, Madrid, Spain, Castellano,D Hospital 12 Octubre, Departamento de Oncología, Madrid, Spain., This study was funded by Pfizer, S.L.U. Medical writing assistance was provided by Esther Tapia, PhD and was founded by Pfizer.
بيانات النشر: BioMed Central
سنة النشر: 2016
المجموعة: Sistema Sanitario Público de Andalucía (SSPA): Repositorio
مصطلحات موضوعية: Adverse events, Guidelines, Renal Cell Carcinoma, Targeted therapy, Carcinoma de células renales, Diarrea, Hipertensión, Neoplasias renales, Cooperación del paciente, Humanos, Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell, Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Diarrhea, Medical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension, Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms, Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care::Attitude to Health::Patient Acceptance of Health Care::Patient Compliance, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Medical Subject Headings::Health Care::Health Services Administration::Patient Care Management::Disease Management
الوصف: Journal Article; ; BACKGROUND The impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group (SOGUG) Guidelines for toxicity management of targeted therapies in metastatic renal cell carcinoma (mRCC) in daily clinical practice. METHODS Data on 407 mRCC patients who initiated first-line targeted therapy during the year before and the year after publication and implementation of the SOGUG guideline program were available from 34 Spanish Hospitals. Adherence to SOGUG Guidelines was assessed in every cycle. RESULTS Adverse event (AE) management was consistent with the Guidelines as a whole for 28.7 % out of 966 post-implementation cycles compared with 23.1 % out of 892 pre-implementation cycles (p = 0.006). Analysis of adherence by AE in non-compliant cycles showed significant changes in appropriate management of hypertension (33 % pre-implementation vs. 44.5 % post-implementation cycles; p < 0.0001), diarrhea (74.0 % vs. 80.5 %; p = 0.011) and dyslipemia (25.0 % vs. 44.6 %; p < 0.001). CONCLUSIONS Slight but significant improvements in AE management were detected following the implementation of SOGUG recommendations. However, room for improvement in the management of AEs due to targeted agents still remains and could be the focus for further programs in this direction. ; Yes
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 1471-2407
العلاقة: http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2084-9Test; Lainez N, García-Doñas J, Esteban E, Puente J, Sáez MI, Gallardo E, et al. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016; 16(1):135; http://hdl.handle.net/10668/2214Test; PMC4763443
DOI: 10.1186/s12885-016-2084-9
الإتاحة: https://doi.org/10.1186/s12885-016-2084-9Test
http://hdl.handle.net/10668/2214Test
حقوق: open access
رقم الانضمام: edsbas.6384597A
قاعدة البيانات: BASE
الوصف
تدمد:14712407
DOI:10.1186/s12885-016-2084-9